Poly (ionic liquid) compositions and their use as tissue adhesives

Abstract

The present invention relates to the discovery of methods of treating a wound in a subject in need thereof. In certain embodiments, the method comprises contacting the wound with a composition comprising gelatin methacrylate and choline acrylate, and then polymerizing the composition to form a polymerized composition having a plurality of choline acrylate functionalized gelatin methacrylate units.

1 . A method of treating a wound in a subject in need thereof, the method comprising:
 (a) contacting the wound with a composition comprising:   a polymer selected from the group consisting of gelatin methacrylate (GelMa) and poly(ethylene glycol) diacrylate (PEGDA);   choline acrylate; and   at least one photoinitiator; and   (b) exposing the composition to at least one wavelength of light capable of activating the at least one photoinitiator, thereby polymerizing the composition.   
     
     
         2 . The method of  claim 1 , wherein the composition comprises about 1:4 to about 4:1 choline acrylate to polymer. 
     
     
         3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein at least one photoinitiator is selected from the group consisting of eosin Y, 2-hydroxy-2-methylpropiophenone, 2-methyl-4′-(methylthio)-2-morpholinopropiophenone, lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), and 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure). 
     
     
         5 . The method of  claim 1 , wherein the composition further comprises at least one additional compound selected from the group consisting of triethanolamine (TEOA) and N-vinylcaprolactam (VC). 
     
     
         6 . (canceled) 
     
     
         7 . The method of  claim 1 , wherein the composition comprises about 10% to about 20% (w/v) choline acrylate. 
     
     
         8 . The method of  claim 1 , wherein the composition comprises about 10% to about 30% (w/v) polymer. 
     
     
         9 . The method of  claim 4 , wherein the composition comprises at least one of:
 about 0.1 mM eosin Y;   0.5% (w/v) LAP;   about 1.5% (w/v) TEOA; or   about 1% (w/v) VC.   
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . The method of  claim 1 , wherein the polymerized composition forms an air tight seal or a hemostatic seal on the wound. 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . The method of  claim 13 , wherein the polymerized composition forms a seal having a burst pressure of at least 5 kPa. 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 13 , wherein the polymerized composition forms an antimicrobial seal on the wound. 
     
     
         20 . The method of  claim 19 , wherein the polymerized composition forms an antibacterial seal on the wound. 
     
     
         21 . The method of  claim 13 , wherein the polymerized composition forms a seal capable of inhibiting the growth, proliferation and/or survival of at least one bacterial strain selected from the group consisting of  Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus, Campylobacter rectus, Eubacterium nodatum, Peptostreptococcus micros, Staphylococcus intermedius, Pseudomonas aeruginosa, Acinetobacter baumannii  and  Treponema  sp. 
     
     
         22 . The method of  claim 13 , wherein the polymerized composition retains a seal on the wound for at least 28 days. 
     
     
         23 . The method of  claim 1 , which increases the rate of clotting in the wound. 
     
     
         24 . The method of  claim 1 , wherein the wound is in an organ selected from the group consisting of a liver, a lung, a heart, a stomach, an intestine, a pancreas, a kidney, a bladder, an artery, a vein, a skin, a brain, and a joint tissue. 
     
     
         25 . The method of  claim 1 , wherein the composition is contacted with the wound during a surgical procedure. 
     
     
         26 . The method of  claim 1 , wherein the composition is contacted with the wound via injection. 
     
     
         27 . The method of  claim 1 , which further comprises suturing the wound. 
     
     
         28 . The method of  claim 1 , which does not further comprise suturing the wound. 
     
     
         29 . The method of  claim 1 , wherein the subject is a mammal. 
     
     
         30 . (canceled)